2 registrations that name huperzine A as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT07066826
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Phase 2 and 3
Wanbangde Pharmaceutical Group Co., LTD
About 720 people
Started Aug 29, 2025
In plain words A Phase 2 and 3 study of huperzine A in people 50 to 85, run by Wanbangde Pharmaceutical Group Co., LTD. It plans to enroll about 720 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 85. Conditions: Alzheimer Dementia.
The subject voluntarily agrees to participate in the study and signs the informed consent form jointly with a legally authorized representative (LAR).
Aged ≥50 and ≤85 years, male or female.
Meets the diagnostic criteria for probable Alzheimer's disease (AD) dementia according to the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) guidelines.
Has experienced memory impairment for at least 12 months, with a chronic and progressively worsening course.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Huperzine A Controlled-Release Tablets; Donepezil hydrochloride tablets; Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo
Registered summary
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial. The dose confirmation stage is designed to evaluate the efficacy and safety of different doses of huperzine A controlled-release tablets in patients with mild-to-moderate dementia of the Alzheimer's type, with the goal of providing a basis for dose selection in the subsequent efficacy confirmation stage. The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07784335
Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants
Phase 1
Wanbangde Pharmaceutical Group Co., LTD
About 40 people
Starts Aug 25, 2026 (estimated)
In plain words A Phase 1 study of huperzine A in people 18 to 55, run by Wanbangde Pharmaceutical Group Co., LTD. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 55; healthy volunteers accepted. Conditions: Healhty.
Participants must provide written informed consent prior to the study, with full understanding of the study's objectives, procedures, and potential adverse reactions;
Participants must be able to communicate effectively with the investigators and comply with the protocol requirements throughout the study.
Healthy male or female, aged 18 to 55 years (inclusive);
Body mass index (BMI) range: 19.0 to 26.0 kg/m2 \[BMI = body weight/height2 (kg/m2)\] (inclusive); male weight ≥50 kg, female weight ≥45 kg.
The exclusion criteria are on the listing.
What it tests, as registered
Huperzine A Oral Solution; Placebo
Registered summary
In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID). Ten healthy study participants will be enrolled in each dose group, and randomized to the investigational drug group or the placebo group in a 4:1 ratio (i.e., 8 study participants in the investigational drug group and 2 study participants in the placebo group). An appropriate gender ratio will be ensured within each dose group.